Share on StockTwits

GlaxoSmithKline plc (LON:GSK)‘s stock had its “hold” rating restated by equities researchers at Jefferies Group in a research report issued on Wednesday. They currently have a GBX 1,385 ($23.15) price objective on the stock. Jefferies Group’s price objective points to a potential downside of 1.95% from the company’s current price.

GlaxoSmithKline plc (LON:GSK) opened at 1422.925 on Wednesday. GlaxoSmithKline plc has a one year low of GBX 1200.668 and a one year high of GBX 1706.00. The stock’s 50-day moving average is GBX 1482. and its 200-day moving average is GBX 1583.. The company’s market cap is £68.357 billion.

The company also recently announced a dividend, which is scheduled for Thursday, October 2nd. Shareholders of record on Wednesday, August 6th will be paid a dividend of GBX 19 ($0.32) per share. This represents a dividend yield of 1.28%. The ex-dividend date is Wednesday, August 6th.

GSK has been the subject of a number of other recent research reports. Analysts at Credit Suisse reiterated an “underperform” rating on shares of GlaxoSmithKline plc in a research note on Friday, August 15th. They now have a GBX 1,475 ($24.66) price target on the stock. Separately, analysts at Beaufort Securities reiterated a “buy” rating on shares of GlaxoSmithKline plc in a research note on Monday, August 4th. Finally, analysts at Shore Capital reiterated a “buy” rating on shares of GlaxoSmithKline plc in a research note on Monday, August 4th. Four investment analysts have rated the stock with a sell rating, twelve have assigned a hold rating and six have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus target price of GBX 1,634.81 ($27.33).

GlaxoSmithKline plc (LON:GSK) is global healthcare group, which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.